Roughly 8–10 paragraphs of flowing prose (no subheadings, no bullet points), roughly 1,400–1,600 words. Here is the article:
In a finding that could reshape how women at high risk of breast cancer access genetic services, researchers at The Ohio State University have shown that a fully digital, patient-driven alternative to traditional genetic counseling performs just as well as the gold-standard, counselor-led process. The randomized controlled trial, published in Cancer Causes & Control, tested an online program called Know Your Risk (KYR) against conventional genetic counseling in 866 women who screened at elevated risk for the disease. The results offer a compelling answer to one of modern oncology’s most persistent bottlenecks: a surging demand for genetic testing that has far outstripped the supply of trained genetic counselors.
The scale of the problem is significant. Approximately 15 percent of women in the United States over age 35 qualify as being at elevated risk for breast cancer, defined as a 20 percent or greater lifetime risk according to family history-based risk models. National Comprehensive Cancer Network guidelines recommend that all such women complete genetic counseling as part of the testing process, a two-stage pathway in which a certified counselor collects a detailed personal and family history, explains the possible outcomes of testing, and later helps patients interpret results ranging from pathogenic variants to variants of uncertain significance. But as precision medicine has expanded and routine mammography screening has grown, the workforce of genetic counselors has not kept pace, leaving many eligible women waiting or never accessing services at all.
The KYR intervention was designed to compress and redistribute that process. Rather than a live pre-test counseling session, participants received access to a series of six online educational videos — running from just under three minutes to just over six — covering topics such as breast cancer basics, genetic testing and counseling, elevated risk, test results, and how to talk with family members. The videos were constructed around a narrative arc and grounded in Protection Motivation Theory, a behavioral framework that addresses how people appraise health threats and their capacity to cope with them. Characters in the videos modeled self-efficacy, for example, with one explaining that completing the test “was not hard at all” and could be done entirely through the mail. After each video, participants could request genetic testing directly with a click, and after testing they chose how — and on what agenda — they wanted their post-test counseling to proceed.
The trial enrolled women aged 30 to 64 who underwent routine mammography at The Ohio State University Medical Center between July 2022 and September 2024 and screened at elevated risk using the clinically validated Tyrer-Cuzick risk model. After exclusions and recruitment, 866 women completed a baseline survey and were randomized one-to-one to either the KYR intervention or conventional genetic counseling. All participants who requested testing received a mailed saliva collection kit and were tested with a 48-gene hereditary cancer panel at a CLIA-approved laboratory. The panel also produced a combined risk score integrating Tyrer-Cuzick version 8 modeling with a multiple-ancestry polygenic risk score, though those scores were suppressed whenever a pathogenic variant was found in one of 13 breast-cancer-specific genes on the panel, including BRCA1, BRCA2, ATM, CHEK2, and PALB2.
The primary measure, cancer genetics knowledge, was assessed with a 12-item scale at baseline and again after counseling and testing. Mean scores rose from a baseline of 6.87 to 8.66 in the KYR group and 8.56 in the conventional counseling group — a statistically indistinguishable gain. Using a formal non-inferiority framework with a prespecified margin of 0.6 on the odds ratio scale, the researchers found that the one-sided 95 percent confidence lower bound for the KYR effect fell within the margin, establishing that the digital pathway was non-inferior for knowledge acquisition. Unadjusted, 58.8 percent of KYR participants scored nine or higher on the knowledge scale after the intervention, compared with 58.6 percent of conventionally counseled participants.
Perhaps the more striking result involved risk perception accuracy. Women in the KYR group were actually more likely than conventionally counsed women to estimate their own lifetime breast cancer risk within 10 percentage points of the figure calculated by the genetic counselor using the Tyrer-Cuzick model: 88.4 percent versus 78.8 percent, an adjusted odds ratio of 1.98. Most women in the general population substantially overestimate or underestimate their true risk, and correcting that misperception is one of genetic counseling’s central functions. That a video-based program with a patient-directed follow-up session matched or exceeded that corrective effect suggests the model of care can carry genuine clinical weight, not just administrative convenience.
Attitudes and satisfaction told a similar story. Participants in both arms entered the study with positive views of counseling and testing, and testing attitudes improved slightly more among KYR participants after testing. Satisfaction with genetic counseling — measured on a validated six-item scale — was essentially identical between groups, with both arms averaging 28.5 out of a possible 30. On a single summary item, KYR participants rated their satisfaction marginally higher, 9.7 versus 9.5 on a 10-point scale. Uptake of testing was also high in both groups, with 81.8 percent of KYR participants and 73.4 percent of conventionally counseled participants completing genetic testing, rates that compare favorably with other alternative service delivery models reported in the literature.
The statistical machinery behind these conclusions was appropriately conservative. The investigators used intention-to-treat analyses with mixed-effects logistic and linear regression, adjusting for baseline knowledge and baseline risk perception, and including random intercepts for individual genetic counselors to account for clustering. Sensitivity analyses that assigned the least favorable satisfaction rating to participants who declined testing or skipped post-test counseling still supported non-inferiority. Power calculations, based on an expectation of roughly 350 participants per arm, indicated at least 80 percent power for the binary endpoints and over 94 percent power for the satisfaction endpoint.
Notably, the trial also embedded elements of genomic medicine that are only beginning to enter mainstream counseling practice. Participants in both arms received results that included a combined risk score blending traditional family-history modeling with a polygenic risk score spanning multiple ancestries. Counselors walked participants through how that score was derived and contrasted it with the recalculated Tyrer-Cuzick estimate used to drive screening and management recommendations. While combined risk scores are not yet standard components of genetic counseling, the researchers suggest they may eventually inform screening decisions for cancer, heart disease, and other conditions, making it all the more important that delivery models can convey them clearly. In this trial, women in the digital arm understood their risk at least as well as those in conventional care.
The implications extend beyond breast cancer. Direct-to-consumer genomic testing has exploded in popularity while clinical genetic services remain rationed by workforce constraints, and health systems are increasingly experimenting with chatbots, group counseling, decision aids, and portal-based tools to close the gap. The KYR trial is among the first to rigorously demonstrate that a package combining online pre-test education, direct access testing, and a patient-driven post-test session can match conventional counseling across knowledge, risk perception, attitudes, and satisfaction simultaneously. The model leverages electronic medical record portals — infrastructure most large health systems already possess — making implementation comparatively low-friction.
The authors are careful to note the study’s limitations. It was conducted at a single Midwestern U.S. health system, and its participants were predominantly non-Hispanic White, college-educated, and relatively affluent — 83.1 percent White, 79.0 percent college graduates, and nearly half reporting household incomes above $120,000. Whether the digital model performs equally well in more diverse or less digitally connected populations remains to be tested. The trial also enrolled only women who already met NCCN criteria for testing, so results may not generalize to lower-risk populations considering testing on their own initiative.
Still, the headline finding is hard to dismiss: for women who screen at elevated breast cancer risk, a mostly self-guided digital pathway delivered the same gains in genetic knowledge and equivalent satisfaction, with better self-assessed risk accuracy, than the traditional counselor-led process. The researchers’ next steps will examine the trial’s primary outcomes — whether participants actually follow through on counselor-recommended cancer screening and risk-reducing behaviors such as enhanced MRI surveillance or smoking cessation. If those results hold, the case for patient-driven genetic services will grow considerably stronger, potentially freeing scarce genetic counselors to focus on the complex cases that need them most while extending testing access to the millions of women currently left waiting.
Subject of Research: A randomized controlled trial comparing the online Know Your Risk (KYR) intervention with conventional genetic counseling among women at elevated risk for breast cancer, evaluating cancer genetics knowledge, risk perception accuracy, attitudes toward genetic counseling and testing, and counseling satisfaction.
Subject of Research: Cancer
Article Title: Knowledge of cancer genetics and attitudes about genetic counseling and testing: a randomized trial of the Know Your Risk intervention compared to conventional genetic counseling
Article References: Katz, M. L., Schnell, P. M., Reiter, P. L., Senter, L., Aeilts, A., Spears, C., Cooper, J., Brown, J., Shane-Carson, K. P., Agnese, D. M., Toland, A. E., & Sweet, K. (2026). Knowledge of cancer genetics and attitudes about genetic counseling and testing: a randomized trial of the Know Your Risk intervention compared to conventional genetic counseling. Cancer Causes & Control, 37(7), Article 112. https://doi.org/10.1007/s10552-026-02207-3
Image Credits: AI Generated
DOI: 10.1007/s10552-026-02207-3
Keywords: genetic counseling, genetic testing, breast cancer, Know Your Risk intervention, non-inferiority trial, Tyrer-Cuzick risk model, cancer genetics knowledge, risk perception, patient-driven care, multigene panel testing, women’s health, digital health intervention
Cite Scienmag News
APA MLA Chicago
Nathaniel Bowman. (September 7, 2026). Know Your Risk intervention improves cancer genetics knowledge versus standard counseling. Scienmag. https://scienmag.com/know-your-risk-intervention-improves-cancer-genetics-knowledge-versus-standard-counseling/
Nathaniel Bowman. “Know Your Risk intervention improves cancer genetics knowledge versus standard counseling.” Scienmag, 7 September 2026, https://scienmag.com/know-your-risk-intervention-improves-cancer-genetics-knowledge-versus-standard-counseling/. Accessed 7 September 2026.
Nathaniel Bowman. “Know Your Risk intervention improves cancer genetics knowledge versus standard counseling.” Scienmag. September 7, 2026. https://scienmag.com/know-your-risk-intervention-improves-cancer-genetics-knowledge-versus-standard-counseling/
Copy citation Download RIS
Tags: breast cancer risk assessmentbreast cancer risk assessment toolscancer genetics educationdigital health interventionsdigital health interventions for cancer riskemerging digital solutions in cancer preventiongenetic counselinggenetic literacy and patient outcomesgenetic risk communicationhealthcare access disparities in geneticshealthcare accessibility and innovationhigh-risk breast cancer screeninghigh-risk population screeninginnovative models for genetic counseling deliveryonline genetic testing programspatient-driven genetic educationpatient-driven healthcarepersonalized medicine in cancer preventionrandomized controlled trials in genetic counselingrandomized controlled trials in oncologytelehealth in cancer preventiontelehealth in oncology
